NCT04856774View on ClinicalTrials.gov

Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

March 30, 2024

Study Completion Date

March 30, 2024

Conditions
Advanced Solid Tumors
Interventions
DRUG

SHR-1701；BP102

"Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion~Phase Ib: SHR-1701 30mg/kg + BP102 15mg/kg Q3w as starting dose, until recommended phase 2 dose is determined."

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY